Crossmark

Digital monitoring of disease activity in relapsing–remitting multiple sclerosis

Crossref DOI link: https://doi.org/10.1007/s00415-026-13685-5

Published Online: 2026-03-06

Published Print: 2026-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Molenaar, P. C. G. https://orcid.org/0000-0002-4735-539X
de Jong, D. J.

Hof, S. N.

van Oirschot, P.

Bucur, I. G.

Lam, K. H.

Moraal, B.

Heskes, T. M.

de Groot, V.

Uitdehaag, B. M. J.

de Jong, B. A.

Twisk, J. W. R.

Strijbis, E. M. M.

Killestein, J.
Funding

Funding for this research was provided by:

Health Holland, Top Sector Life Sciences and Health (Grant No. LSHM16060-SGF)

Stichting MS Research (Grant No. 16-946 MS)

Biogen (Unrestricted funding)
License Information

Text and Data Mining valid from 2026-03-01

Version of Record valid from 2026-03-06
More Information

Article History

Received: 16 October 2025

Revised: 4 February 2026

Accepted: 5 February 2026

First Online: 6 March 2026

Declarations

:

: P.C.G. Molenaar has nothing to disclose, D.J. de Jong has nothing to disclose, S.N. Hof has nothing to disclose, P. van Oirschot was an employee of Sherpa B.V. (manufacturer of the MS sherpa app), I.G. Bucur is funded by Radboud Healthy Data, K.H. Lam has nothing to disclose, B. Moraal has nothing to disclose, T.M. Heskes has nothing to disclose, V. de Groot has nothing to disclose, B.M.J. Uitdehaag has received research support and/or consultancy fees from Biogen Idec, Genzyme, Merck, Serono, Novartis, Roche, Teva and Immunic Therapeutics, B.A. de Jong has received grants from Dutch MS Research Foundation, National MS Foundation and Dutch MS Society and is member of the medical advisory board of the Dutch MS Society and chair of the committee of the Dutch National MS registration of the Netherlands Society of Neurology, J. Twisk has nothing to disclose, E.M.M. Strijbis has speaker relations with Merck and Novartis (all payments to institution), J. Killestein has received consulting fees for F. Hoffmann-La Roche, Biogen, Teva, Merck, Novartis and Sanofi/Genzyme (payments to institution); reports speaker relationships with F. Hoffmann-La Roche, Biogen, Teva, Merck, Novartis and Sanofi/Genzyme (payments to institution); adjudication committee of MS clinical trials of Immunic (payments to institution).

: Use of data from the Dutch-MSR was approved by the medical research ethics committee of the Amsterdam UMC (reference 2021.0506).

: Written informed consent from all participants in this study was collected prior to inclusion.

Document is current

Any future updates will be listed below